The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2026 | Real-world insights into the use of belantamab mafodotin-based combinations in R/R MM
Elena Zamagni, MD, PhD, University of Bologna, Bologna, Italy, discusses the real-world use of belantamab mafodotin-based combinations in relapsed/refractory multiple myeloma (R/R MM), noting that physicians select combinations with bortezomib and pomalidomide equally often. Dr Zamagni highlights that the bortezomib combination is being used in daratumumab-refractory patients, and also shows promise as an option for elderly and frail patients. This interview took place at the 23rd International Myeloma Society (IMS) Annual Meeting in Glasgow, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Yes, we show this data first of all showing that the two bela combos with bortezomib and pomalidomide are equally selected and I think this is important because in the randomized trial, the inclusion population was not identical. So in the pomalidomide combination, patients lenalidomide and daratumumab refractory were present, but not in the bortezomib combination. But the real-life use is demonstrating that physicians are choosing according to the patients and not to this initial inclusion criteria...
Yes, we show this data first of all showing that the two bela combos with bortezomib and pomalidomide are equally selected and I think this is important because in the randomized trial, the inclusion population was not identical. So in the pomalidomide combination, patients lenalidomide and daratumumab refractory were present, but not in the bortezomib combination. But the real-life use is demonstrating that physicians are choosing according to the patients and not to this initial inclusion criteria. So there is a widespread use of the bela-bortezomib combo also in daratumumab refractory patients and I think that the real world will be able to demonstrate the clinical activity of the combination also in this setting. And also this month of use with this compassionate access that we had in Italy demonstrated that it’s a wonderful option for more elderly and frail patients. So there is quite a big use of this combination. So I’m doing this in my routine practice. For sure, in the future, we’ll also have a bispecific in second line, but currently for the second line treatment of patients it’s a very good option.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
